TP53 and acute myeloid leukemia: Notably, PD-L1 expression is significantly increased in TP53-mutated AML/MDS, which is associated with MYC upregulation and marked downregulation of its negative regulator miR-34a (a p53 transcription target) compared to the TP53 wild-type disease [104].